Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
{{output}}
Background: Indoleamine-2,3-dioxygenase (IDO) helps orchestrate immune suppression and checkpoint inhibitor resistance in hepatocellular carcinoma (HCC). BMS-986,205 is a novel oral drug that potently and selectively inhibits IDO... ...
